Molecular Partners (MOLN) Stock Statistics & Valuation Metrics

Molecular Partners has a market cap or net worth of $164.17M. The enterprise value is $66.22M.

Molecular Partners has 40,374,640 shares outstanding. The number of shares has decreased by -2.65% in one year.

Molecular Partners’s return on equity (ROE) is -0.38 and return on invested capital (ROIC) is -41.10%.

The current PE Ratio of Molecular Partners is -2.65. Molecular Partners’s PEG ratio is 0.19.

In the last 12 months, Molecular Partners had revenue of 4.97M and earned -54.04M in profits. Earnings per share was -1.63.

In the last 12 months, operating cash flow was -57.98M and capital expenditures -723.00K, giving a free cash flow of -58.71M billion.

Molecular Partners pays an annual dividend of ―, resulting in a dividend yield of ―

Molecular Partners upcoming earnings date is Aug 25, 2025, TBA Not Confirmed.

Molecular Partners as a current ratio of 14.31, with Debt / Equity ratio of 1.73%

In the past 12 months, Molecular Partners has paid 2.00K in taxes.

Molecular Partners EV to EBITDA ratio is -1.58, with an EV/FCF ratio of -1.36.

Molecular Partners has $149.44M in cash and marketable securities with CHF0.00 in debt, giving a net cash position of -$147.00M billion.

Gross margin is -447.10%, with operating margin of -1231.73%, and net profit margin of -1087.38%.

The average price target for Molecular Partners is $10.38, which is 11.43% higher than the current price. The consensus rating is Strong Buy